TABLE 3.
Compounds showing effectiveness against HHV-6
| Druga | Prodrug | Chemical structure | HHV-6 target | EC50b (μM) | Clinical use | Reference(s) |
|---|---|---|---|---|---|---|
| Ganciclovir | Valganciclovir | Nucleoside analogue | DNA polymerase | 2.0–68.6 | Yes (approved for HCMV) | 203, 204 |
| Foscarnet | None | Pyrophosphate analogue | DNA polymerase | 6–86 | Yes (approved for HCMV) | 203, 204 |
| Cidofovir | Brincidofovir | Nucleotide analogue | DNA polymerase | 0.3–46 | Yes (approved for HCMV) | 203, 204 |
| H2G | Valomaciclovir | Nucleoside analogue | DNA polymerase | 36.6 | Yes (clinical trials) | 214–216 |
| Cyclopropavir | 6-Deoxycyclopropavir | Nucleoside analogue | DNA synthesis step | 0.5–7 | No (pharmaceutical development) | 203, 204, 217–219 |
| S2242 | None | Nucleoside analogue | DNA polymerase | 0.02–0.03 | No (pharmaceutical development) | 216, 220 |
| 3-Deaza-HPMPA | None | Nucleotide analogue | DNA polymerase | 1.2–1.4 | No (discontinued development) | 220 |
| CMV423 | None | Indolizinecarboxamide | Tyrosine kinasec | 0.017–0.053 | No (discontinued development) | 203, 204, 222 |
| Artesunate | None | Semisynthetic derivative of artemisinin | Sp1/NF-κB activation pathwaysc | 3.8 | Yes (approved for malaria) | 212, 213 |
a
No drug is officially approved for use on HHV-6.
b
EC50, 50% effective dose (range or unique value, according to the data in referenced studies).
c
Cellular component target.